The company announced the results during trading hours today, 27 April 2012.
Meanwhile, the BSE Sensex was up 78.02 points or 0.46% to 17,208.69.
On BSE, 2.45 lakh shares were traded in the counter as against average daily volume of 1.47 lakh shares in the past one quarter.
The stock hit a low of Rs 225.75 so far during the day, which is a 52-week low for the counter. The stock hit a high of Rs 238.50 so far during the day. The stock had hit a 52-week high of Rs 390.05 on 27 April 2011.
The stock had underperformed the market over the past one month till 26 April 2012, falling 0.63% compared with the Sensex's 0.46% gain. The scrip had also underperformed the market in past one quarter, declining 13.59% as against Sensex's 0.31% gain.
The mid-cap biotechnology major has an equity capital of Rs 100 crore. Face value per share is Rs 5.
Biocon's consolidated net profit fell 2.98% to Rs 97.80 crore on 25.38% growth in total income to Rs 611.49 crore in Q4 March 2012 over Q4 March 2011. Consolidated net profit fell 7.91% to Rs 338.43 crore on 15.64% growth in total income to Rs 2148.32 crore in the year ended 31 March 2012 over the year ended 31 March 2011.
Branded Formulations division grew 39% year-on-year (YoY) in FY 2012, reflecting the accelerated growth and growing clout of chronic therapies in the market, Biocon said.
The company said FY 2012 saw strong continuing momentum with recent investment in chemistry, biology and biologics services coming into fruition. In FY 2012, Syngene and Clinigene together grew revenues by 29% YoY on the back of strong expansion from existing customers and a steady flow of new customer contracts, the company said.
During the year, Syngene International acquired 100% of the shareholding of Clinigene International from Biocon to ensure seamless operational integration of the combined research service offerings, Biocon said in a statement.
Commenting on the results, Dr Kiran Mazumdar Shaw, CMD, Biocon said, I am pleased with the overall performance that we have delivered in FY 2012. Group sales have risen by 16% and PAT was sustained at previous levels despite lower net licencing income. We have delivered particularly strong growth in our Research Services & Branded Formulations business verticals. Our balance sheet remains robust and our cash position is strong. The global economic outlook remains uncertain. However, we are confident that we will make significant progress across all our businesses.
Biocon's board of directors at a meeting held on Thursday, 26 April 2012, recommended a final dividend of Rs 5 per share for the year ended March 2012.
Biocon is a biotechnology company with a strategic focus on biopharmaceuticals and research services. Established in 1978 by Dr Kiran Mazumdar-Shaw, the Group is an integrated, innovation-driven healthcare enterprise with offerings that traverse the entire drug development value chain. The company delivers solutions to partners and customers in over 70 countries across the globe.